Evidence map›Paper›PMID 31260448›Full record

ArticlePLoS genetics2019

XBP1 signalling is essential for alleviating mutant protein aggregation in ER-stress related skeletal disease.

Katarzyna A Piróg, Ella P Dennis, Claire L Hartley, Robert M Jackson, Jamie Soul, Jean-Marc Schwartz, John F Bateman, Raymond P Boot-Handford, Michael D Briggs

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Katarzyna A PirógInstitute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.ORCID 0000-0003-0736-3296
Ella P DennisInstitute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
Claire L HartleyWellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, United Kingdom.
Robert M JacksonInstitute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
Jamie SoulWellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, United Kingdom.ORCID 0000-0003-2255-6459
Jean-Marc SchwartzWellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-6472-0184
John F BatemanMurdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0001-8542-0730
Raymond P Boot-HandfordWellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-6167-8419
Michael D BriggsInstitute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
Newcastle University · GBWellcome Centre for Cell-Matrix Research · GBMurdoch Children's Research Institute · AU

Funding

Medical Research Council MR/P020941/1Wellcome TrustWellcome Trust 084353/Z/07
6 · The paper itself

Abstract

The unfolded protein response (UPR) is a conserved cellular response to the accumulation of proteinaceous material in endoplasmic reticulum (ER), active both in health and disease to alleviate cellular stress and improve protein folding. Multiple epiphyseal dysplasia (EDM5) is a genetic skeletal condition and a classic example of an intracellular protein aggregation disease, whereby mutant matrilin-3 forms large insoluble aggregates in the ER lumen, resulting in a specific 'disease signature' of increased expression of chaperones and foldases, and alternative splicing of the UPR effector XBP1. Matrilin-3 is expressed exclusively by chondrocytes thereby making EDM5 a perfect model system to study the role of protein aggregation in disease. In order to dissect the role of XBP1 signalling in aggregation-related conditions we crossed a p.V194D Matn3 knock-in mouse model of EDM5 with a mouse line carrying a cartilage specific deletion of XBP1 and analysed the resulting phenotype. Interestingly, the growth of mice carrying the Matn3 p.V194D mutation compounded with the cartilage specific deletion of XBP1 was severely retarded. Further phenotyping revealed increased intracellular retention of amyloid-like aggregates of mutant matrilin-3 coupled with dramatically decreased cell proliferation and increased apoptosis, suggesting a role of XBP1 signalling in protein accumulation and/or degradation. Transcriptomic analysis of chondrocytes extracted from wild type, EDM5, Xbp1-null and compound mutant lines revealed that the alternative splicing of Xbp1 is crucial in modulating levels of protein aggregation. Moreover, through detailed transcriptomic comparison with a model of metaphyseal chondrodysplasia type Schmid (MCDS), an UPR-related skeletal condition in which XBP1 was removed without overt consequences, we show for the first time that the differentiation-state of cells within the cartilage growth plate influences the UPR resulting from retention of a misfolded mutant protein and postulate that modulation of XBP1 signalling pathway presents a therapeutic target for aggregation related conditions in cells undergoing proliferation.

Indexed as

MutationAlternative SplicingAnimalsApoptosisCell ProliferationCells, CulturedChondrocytesDisease Models, AnimalEndoplasmic Reticulum StressGene Expression ProfilingHumansMatrilin ProteinsMiceOsteochondrodysplasiasProtein AggregatesSignal TransductionMATN3 protein, humanMatrilin ProteinsProtein AggregatesX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID31260448
PMCPMC6625722
OpenAlexW2953722030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.